| Angus Mcrae Warren, MD | |
|
250 Hospital Pl, Soldotna, AK 99669-7559 | |
| (907) 714-4404 | |
| Not Available |
| Full Name | Angus Mcrae Warren |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 20 Years |
| Location | 250 Hospital Pl, Soldotna, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396946794 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 2007-00841 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Peninsula General Hospital | Soldotna, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Peninsula General Hospital Inc | 4587552575 | 85 |
News Archive
BG Medicine today announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicine's common stock at $7.00 per share, less underwriting discounts and commissions.
Takara Bio USA, Inc. (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., and Integrated DNA Technologies (IDT) today announced a new collaboration to support targeted RNA sequencing.
Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the expansion of its capabilities for cardiac safety and cardiovascular efficacy studies in the company's early phase diabetes and obesity clinical trials.
Type 2 diabetes can be reversed following an intensive weight management program, according a randomized trial in adults who have had the condition for up to 6 years, published in The Lancet.
NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.
› Verified 8 days ago
| Entity Name | Central Peninsula General Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528062429 PECOS PAC ID: 4587552575 Enrollment ID: O20040310000598 |
News Archive
BG Medicine today announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicine's common stock at $7.00 per share, less underwriting discounts and commissions.
Takara Bio USA, Inc. (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., and Integrated DNA Technologies (IDT) today announced a new collaboration to support targeted RNA sequencing.
Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the expansion of its capabilities for cardiac safety and cardiovascular efficacy studies in the company's early phase diabetes and obesity clinical trials.
Type 2 diabetes can be reversed following an intensive weight management program, according a randomized trial in adults who have had the condition for up to 6 years, published in The Lancet.
NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.
› Verified 8 days ago
| Entity Name | South Peninsula Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679566269 PECOS PAC ID: 5395636930 Enrollment ID: O20040323000583 |
News Archive
BG Medicine today announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicine's common stock at $7.00 per share, less underwriting discounts and commissions.
Takara Bio USA, Inc. (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., and Integrated DNA Technologies (IDT) today announced a new collaboration to support targeted RNA sequencing.
Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the expansion of its capabilities for cardiac safety and cardiovascular efficacy studies in the company's early phase diabetes and obesity clinical trials.
Type 2 diabetes can be reversed following an intensive weight management program, according a randomized trial in adults who have had the condition for up to 6 years, published in The Lancet.
NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Angus Mcrae Warren, MD 35495 Hager Blvd, Soldotna, AK 99669-6403 Ph: (907) 398-2201 | Angus Mcrae Warren, MD 250 Hospital Pl, Soldotna, AK 99669-7559 Ph: (907) 714-4404 |
News Archive
BG Medicine today announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicine's common stock at $7.00 per share, less underwriting discounts and commissions.
Takara Bio USA, Inc. (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., and Integrated DNA Technologies (IDT) today announced a new collaboration to support targeted RNA sequencing.
Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the expansion of its capabilities for cardiac safety and cardiovascular efficacy studies in the company's early phase diabetes and obesity clinical trials.
Type 2 diabetes can be reversed following an intensive weight management program, according a randomized trial in adults who have had the condition for up to 6 years, published in The Lancet.
NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.
› Verified 8 days ago
Dr. Stephen L. Hileman, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 250 Hospital Place, Central Peninsula General Hospital, Soldotna, AK 99669 Phone: 907-714-4444 Fax: 907-714-4699 | |
Aaron Michael Wonnacott, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Hospital Pl, Soldotna, AK 99669 Phone: 907-714-4444 | |
James Levine, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Hospital Pl, Soldotna, AK 99669 Phone: 907-714-4444 | |
Cynthia Sue Mildbrand, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 250 Hospital Pl, Soldotna, AK 99669 Phone: 907-714-4444 | |
Dr. Charles Chris Mickelson, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Hospital Pl, Soldotna, AK 99669 Phone: 907-714-4444 | |
Dr. Robert Ledda, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Hospital Pl, Soldotna, AK 99669 Phone: 907-714-4444 |